Immunicon Pharma Services offers assay development and clinical trial testing services to some of the largest pharmaceutical and biotechnology companies in connection with cancer drug development programs. These companies diligently search for tools to move drug targets from discovery to product launch as cost-effectively and quickly as possible. Rare cells, such as Circulating tumor cells (CTCs) and circulating endothelial cells (CECs), can be used as biomarkers, and protein and gene expression associated with these rare cells may be useful to understand mechanism of action, pharmacodynamics and efficacy of cancer drugs. As an expert in rare cell analysis, Immunicon offers drug developers a unique partnership opportunity to accelerate their programs using CTCs and CECs or molecular biomarkers in clinical trials. Immunicon offers assay development services for its CellTracks(R) System rare cell technology, including biomarker assays for protein markers or fluorescence in situ hybridization (FISH) targets and new assay kit development for analysis of other rare cells. Immunicon's clinical trial testing services include testing CTCs or CECs as biomarkers in clinical trials and rare cell enrichment for downstream molecular analysis.
The CellCapture CTC Mouse/Rat Kit enables pre-clinical studies using animal models. The CellCapture Kit uses a manual test procedure to capture CTCs in a few drops of mouse blood and the cells are counted and characterized using the CellTracks(R) Analyzer II. This kit will enable scientists to conduct efficacy studies in v ery early drug studies and may streamline this important phase of drug development. The CellCapture CTC Mouse Kit and CellTracks Analyzer II will be sold by the Immunicon sales team directly.
The EasyCount System is a fluorescent microscopy-based imaging system that accurately counts dead and live nucleated cells and automatically calculates cell viability, in a single test. Currently, most cell counting procedures are done manually using a hemacytometer and a microscope, which is a time-consuming and tedious process. The EasyCount System together with the EasyCount ViaSure(TM) Kit automate this routine function, eliminating the variability associated with the subjective interpretation of manual methods. The researcher can perform up to six tests at a time using the EasyCount Slide6(TM) Multi-Well Slide provided with the EasyCount ViaSure Kit and the instrument reports total and live cell counts and viability calculation in less than one minute per test. Immunicon will target research laboratories and industrial accounts including bioprocessing facilities in the pharmaceutical, biotechnology and diagnostics sectors, where rapid, accurate cell counting is valued highly by users.
About Immunicon Corporation
Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products, and is providing certain analytical services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon has developed platform technologies to identify, count and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon's products and underlying technology platforms also have application in cancer research and may have applications in other fields of medicine, such as c ardiovascular and infectious diseases. For more information, please visit www.immunicon.com.
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as "hope," "may," "believe," "anticipate," "plan," "expect," "intend," "assume," "will" and similar expressions. Forward-looking statements contained in this press release include, among others, statements relating to the anticipated clinical utility of Immunicon's products and services and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, are based on the current expectations and intent of the management of Immunicon and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by these statements. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, including, but not limited to, risks and uncertainties associated with: Immunicon's dependence on Veridex, LLC, a Johnson & Johnson company, in the field of cancer cell analysis; the ability to earn license and milestone payments under Immunicon's agreement with Veridex; Immunicon's capital and financing needs; research and development and clinical trial expenditures; commercialization of product candidates; Immunicon's ability to obtain licenses from third parties to commercialize products; Immunicon's ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon's customers; compliance with applicable manufacturing standards; retaining key personnel; delays in the development of new products or pl anned improvements to products; effectiveness of products compared to competitors' products; protection of Immunicon's intellectual property; conflicts with third party intellectual property; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon's industry. These factors are discussed in more detail in Immunicon's filings with the Securities and Exchange Commission. Except as required by law, Immunicon accepts no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for modifications made to this document by Internet or wire services.
"CellTracks" is registered trademarks of Immunivest Corporation, a wholly owned subsidiary of Immunicon Corporation. "Immunicon" and the Immunicon Corporation logo are registered trademarks of Immunicon Corporation. "CellCapture," "EasyCount," "ViaSure" and "Slide6" are trademarks of Immunivest Corporation. ALL RIGHTS RESERVED.
James G. Murphy
SVP of Finance & Administration, CFO
Investors/Media: Tierney Communications